Medivir To Acquire BioPhausia's Commercial Platform To Market HCV Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivir has a made a bid for BioPhausia in order to use the company as a commercial platform from which to market its hepatitis C drug, TMC435. Medivir sees the matter as urgent, as its drug is two years behind the competition.